Loading
CRLF2 (Cytokine receptor-like factor 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Lung cancer, Acute lymphoblastic leukaemia and 2 more.
Receptor for thymic stromal lymphopoietin (TSLP). Forms a functional complex with TSLP and IL7R which is capable of stimulating cell proliferation through activation of STAT3 and STAT5. Also activates JAK2.
CIViC holds 5 clinical evidence items and 0 assertions across 5 variants, naming Sirolimus and JAK Inhibitor I. Open Targets scores its association with cancer at 0.62 (direct and indirect evidence; datatypes literature 0.63, animal model 0.36, somatic mutation 0.80). IntOGen calls it a driver in 1 cohort (0 activating, 1 loss-of-function), covering Lung Adenocarcinoma.
In plain words · CRLF2 (Cytokine receptor-like factor 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Lung cancer, Acute lymphoblastic leukaemia and 2 more.
CRLF2 (Cytokine receptor-like factor 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Lung cancer, Acute lymphoblastic leukaemia and 2 more.
Receptor for thymic stromal lymphopoietin (TSLP). Forms a functional complex with TSLP and IL7R which is capable of stimulating cell proliferation through activation of STAT3 and STAT5.
No product in this corpus aims at CRLF2 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
Tumour-specific alteration: the catalogues call it a tumour suppressor (IntOGen finds it knocked out more often than chance); what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA CRLF2: RNA tissue enhanced (bone marrow 2 nTPM, gallbladder 1 nTPM, lymphoid tissue 1 nTPM); blood lineage lineage enriched (dendritic cells 1 nTPM); no normal tissue stained high. Distribution: 3 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Skin cancer (all types), Lung cancer (all types), Leukaemia); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt Q9HC73; CIViC gene CRLF2; IntOGen CRLF2; Human Protein Atlas CRLF2 tissue; Open Targets ENSG00000205755 associations
First described 2001. Earliest sequence paper UniProt cites for the protein: Zhang et al, Biochem. Biophys. Res. Commun, 2001, "Identification of a novel type I cytokine receptor CRL2 preferentially expressed by human dendritic cells and activated monocytes". Source.
Sources: HGNC HGNC:14281 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9HC73 (protein name, function text, keywords and locations (REST API)); CIViC gene CRLF2 (5 evidence items, 0 assertions, 5 variants; diseases: Acute Lymphoblastic Leukaemia, B-cell Adult Acute Lymphocytic Leukaemia, Childhood B-cell Acute Lymphoblastic Leukaemia, B-lymphoblastic Leukaemia/lymphoma (GraphQL API, CC0)); Open Targets ENSG00000205755 (association with cancer (MONDO_0004992) 0.62; per-cancer scores at or above 0.5: melanoma 0.52, skin cancer 0.56, lung cancer 0.53 (GraphQL API, CC0)); IntOGen CRLF2 (driver in 1 cohort (Act 0, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Receptor for thymic stromal lymphopoietin (TSLP). Forms a functional complex with TSLP and IL7R which is capable of stimulating cell proliferation through activation of STAT3 and STAT5. Also activates JAK2. Implicated in the development of the haematopoietic system. Location: Cell membrane; Secreted (UniProt). Locus Xp22.3 and Yp11.3 (HGNC).
RNA: tissue enhanced (bone marrow 2 nTPM, gallbladder 1 nTPM, lymphoid tissue 1 nTPM), detected in some normal tissues. Blood: lineage enriched (dendritic cells 1 nTPM).
No normal tissue stained high.
RNA cancer enhanced: Thyroid Carcinoma 2 pTPM.
No cancer sample stained medium or high.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"CRLF2" OR ABSTRACT:"CRLF2" OR TITLE:"cytokine receptor like factor 2" OR ABSTRACT:"cytokine receptor like factor 2" OR TITLE:"Cytokine receptor-like factor 2" OR ABSTRACT:"Cytokine receptor-like factor 2" OR TITLE:"CRL2" OR ABSTRACT:"CRL2" OR TITLE:"TSLPR" OR ABSTRACT:"TSLPR") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CRLF2, not a curated reading list.